The development of intestinal organoids from single adult intestinal stem cells in vitro recapitulates the regenerative capacity of the intestinal epithelium\(^1\). Here we unravel the mechanisms that orchestrate both organoid formation and the regeneration of intestinal tissue, using an image-based screen to assay an annotated library of compounds. We generate multivariate feature profiles for hundreds of thousands of organoids to quantitatively describe their phenotypic landscape. We then use these phenotypic fingerprints to infer regulatory genetic interactions, establishing a new approach to the mapping of genetic interactions in an emergent system. This allows us to identify genes that regulate cell-fate transitions and maintain the balance between regeneration and homeostasis, unravelling previously unknown roles for several pathways, among them retinoic acid signalling. We then characterize a crucial role for retinoic acid nuclear receptors in controlling exit from the regenerative state and driving enterocyte differentiation. By combining quantitative imaging with RNA sequencing, we show the role of endogenous retinoic acid metabolism in initiating transcriptional programs that guide the cell-fate transitions of intestinal epithelium, and we identify an inhibitor of the retinoic X receptor that improves intestinal regeneration in vivo.

### Phenotypic landscape

We devised an image-based screen with a chemical genetics approach, generating intestinal organoids from single cells over the course of four days in the continuous presence of 2,789 selected compounds, including inhibitors of kinases, nuclear hormone receptors, transcriptional regulators and other target classes (Supplementary Table 1). Organoids were stained for markers of enterocytes and Paneth cells (using antibodies specific to the enzyme aldolase\(^{14,15}\) and lysozyme\(^{16}\), respectively), for DNA (using 4’m,6-diamidino-2-phenylindole, DAPI) and for total protein content, and imaged with a high-throughput microscope (generating roughly 10\(^7\) images). We profiled approximately 450,000 organoids using a multivariate feature set that showed reproducible, significant and condition-specific effects in organoids treated with active controls, namely the γ-secretase inhibitor\(^{17}\) DAPT and the glycogen synthase kinase-3β (GSK-3β) inhibitor\(^{18}\) CHIR99021 (Fig. 1a and Extended Data Fig. 1a–i).

We clustered organoids by phenotypic similarity\(^{19}\), assigning every organoid to one of the 15 identified phenotypic classes. To improve interpretability, we assigned the classes to seven major biological processes: intestinal stem cells, progenitor cells, early differentiation, absorptive enterocytes distal from the crypt\(^{12}\), organoids recapitulating the regeneration of the epithelium and subsequent re-establishment of homeostasis\(^{12}\).

| Ilya Lukonin\(^{12}\), Denise Serra\(^{12}\), Ludivine Challet Meylan\(^{1}\), Katrin Volkmann\(^{1}\), Janine Baaten\(^{9}\), Rui Zhao\(^{3}\), Shelly Meeusen\(^{3}\), Karyn Colman\(^{3}\), Francisca Maurer\(^{1}\), Michael B. Stadler\(^{1,4}\), Jeremy Jenkins\(^{5}\) & Prisca Liberali\(^{1,2}\) |
| --- |

The intestinal epithelium consists of a single layer of polarized cells, which are arranged into regular protruding units, or villi, that host differentiated cells, interspaced by crypts composed of stem cells and secretory Paneth cells\(^{3,4}\). At the crypt periphery, cells divide rapidly before migrating upward along the villus\(^{5}\) and terminally differentiating\(^6\). Intestinal epithelial cells feature unique plasticity\(^7\) that allows them to dedifferentiate and replenish the pool of cycling cells lost upon damage\(^8,9\). During regeneration, tissue pattern and homeostasis are restored through numerous signalling pathways\(^10,11\). It is, however, poorly understood how the spatial organization is regulated and coordinated, especially in the adult intestine after regeneration.

Intestinal organoids recapitulate the ability of intestinal tissue to regenerate and return to homeostasis following damage\(^1,2,4\): an entire organoid develops from a single cell, forming a self-organized structure\(^12,13\). Initially, single cells enter a regenerative state that is dependent on the transcriptional regulator YAP, and form a symmetric cyst\(^1\). Subsequently, symmetry is broken by the emergence of Paneth cells that define and maintain the crypt\(^4\), followed by the differentiation of absorptive enterocytes distal from the crypt\(^12\). Organoids thus recapitulate the regeneration of the epithelium and subsequent re-establishment of homeostasis\(^12\).

Here we have developed an image-based screening platform in organoids cultured from single cells in order to characterize the phenotypic landscape of organoid development and infer functional genetic interactions. We then focused on conditions that improve the regeneration potential, and discovered a role for nuclear retinoic acid receptors in the response to intestinal damage and homeostasis both in vitro and in vivo.
A roughly 400,000 organoid dataset. CETP, PDCD1, and PRKCH were among the 101 genes with tSNE values of at least 0.175. For the inner network, node colour and edge colour are explained in the key on the left. Highlighted nodes show off-diagonal interactors. The outer networks show detected subnetworks. Edge thicknesses show HIS values: edges with the highest HIS value per node are shown. Node outlines show compound modality (inhibitor or activator). KEGG enrichments are shown per phenotype (inner circle) and subnetwork (outer circle). Infl. med. reg., inflammation-mediated regulation.

Fig. 1 | Phenotypic landscape and map of functional genetic interactions in intestinal organoids. a, Screening workflow: organoid-level multivariate feature array, clustering by similarity and generation of phenotypic fingerprints for each condition. D, DAPI; Aldob, aldolase B; Lyz, lysozyme; mass disp., mass displacement for the indicated immunofluorescence channels; tSNE, t-distributed stochastic neighbour embedding. b, Left, main panel: identified phenotypic clusters, representative images and schematic representation of the phenotypes. Right, network of HIS interactions (for HIS values of at least 0.175) between 101 genes. For the inner network, node colour and edge colour are explained in the key on the left. Highlighted nodes show off-diagonal interactors. The outer networks show detected subnetworks. Edge thicknesses show HIS values: edges with the highest HIS value per node are shown. Node outlines show compound modality (inhibitor or activator). KEGG enrichments are shown per phenotype (inner circle) and subnetwork (outer circle). Infl. med. reg., inflammation-mediated regulation. a, b, Images are maximum intensity projections (MIPs) of confocal z-stacks, showing nuclear staining (DAPI) and antibody staining for lysozyme and aldolase B.

Phenotype (classes 1–3, ‘mature organoids’); others included ‘Paneth cell hyperplasia’ (classes 5–7), ‘Wnt hyperactivation’ (classes 8 and 9), ‘progenitor-reduced’ (class 10), and organoids consisting only of enterocytes (classes 14 and 15, ‘enterocysts’) or lacking both differentiated cell types (classes 11–13, ‘regenerative’) (Fig. 1b). A subpopulation (class 13) of the latter phenotype is reminiscent of the YAPI-overexpression and regenerative-state phenotype, whereas classes 11 and 12 are more similar to an undifferentiated state and might be primed to become enterocytes over time.

To avoid any loss of fidelity, we generated a 15-element phenotypic fingerprint for every compound. We identified 301 compounds from the primary and validation screens that produced strong phenotypes and high reproducibility scores, corresponding to 207 unique target genes (Extended Data Fig. 2d–h and Supplementary Table 1).
Twenty-nine genes were targeted by two or more compounds, resulting in highly similar phenotypic fingerprints. Some of these genes belong to signalling pathways that have previously been implicated in organoid development and homeostasis (such as Wnt, Notch and transforming growth factor-β (TGF-β) pathways), but others contribute to pathways that have not hitherto been ascribed to organoid development (such as nuclear receptor signalling; Extended Data Fig. 3a–f and Supplementary Table 1).

Mapping functional interactions

Using the hierarchical interaction score (HIS)\textsuperscript{20,21} to investigate the phenotypic fingerprints of the 207 gene hits identified above, we inferred roughly 6,800 HIS interactions that are enriched in interactions reported by the Search Tool for Retrieving Interacting Genes/Proteins (STRING) database, and co-annotated gene pairs. We next determined the optimal HIS threshold in order to create a map of functional genetic interactions that underlie the development of intestinal organoids (Fig. 1b, Extended Data Fig. 4a–d and Supplementary Table 1).

Network connectivity identified upstream regulators and key players, including β-catenin (CTNNB1; Extended Data Fig. 4e), consistent with the crucial role of canonical Wnt signalling\textsuperscript{22,23}. In addition, we identified six highly interconnected subnetworks (Fig. 1b) showing specific fingerprints and functional annotation enrichments. Interestingly, compounds that activate or inhibit Wnt signalling (GSK3β and PORCN inhibitors, respectively) both led to an increase in the abundance of symmetry-breaking-deficient phenotypes (Fig. 1b), but were assigned to different specific clusters, consistent with different phenotypic outcomes over time (Extended Data Fig. 2b).

For validation, we carried out functional studies of several identified target genes from different phenotypes: Psen1 (from ‘Paneth cell hyperplasia’), Casr (encoding a calcium-sensing receptor; from ‘Wnt hyperactivation’), Akt1 (from the ‘enterocyst’ phenotype) (Extended Data Fig. 4f–h) and Rxra (from the ‘regenerative’ phenotype; Fig. 2).

RXR controls exit from regenerative state

We focused on the ‘regenerative’ phenotype, observing the highest penetrance when using Cpd2170 (RXRI), an antagonist\textsuperscript{24} of retinoic acid receptor (RXR)-α (Extended Data Fig. 4i, j and Supplementary Table 1). We confirmed that RXR inhibition induced a near-complete absence of enterocytes, whereas an RXR agonist (NRX 194204), all-trans retinoic acid (atRA) or 9-cis retinoic acid (9cis-RA), individually and in combination, increased enterocyte differentiation but could not rescue the RXRi-induced differentiation defect, hinting at a retinoic acid-independent role of RXR (Fig. 2a and Extended Data Fig. 5a, b). RXRI treatment at day 0 also resulted in a lack of Paneth cells, suggesting a symmetry-breaking defect (Extended Data Fig. 5c). To investigate the initial differentiation of Paneth cells, we turned to notch signalling and YAP1 localization. In RXRI-treated organoids at day 2.5, we observed an absence of cells expressing the Notch ligand DLL1 and a strong homogenous nuclear retention of YAP1; by contrast, in atRA-treated organoids YAP1 was invariably localized to the cytoplasm (Fig. 2b).

Therefore, both RXRI- and atRA-treated organoids exhibit a defect in symmetry breaking, accompanied by homogenous YAP1 localization. However, RXRI-treated organoids with nuclear YAP1 retained a regenerative YAP-dependent state\textsuperscript{25,26} and maintained an active cell cycle (Extended Data Fig. 5d), whereas atRA-treated organoids with cytoplasmic YAP1 underwent differentiation to enterocytes.

We then treated organoids after symmetry breaking, when YAP1 is predominantly inactive (day 3). RXRI-treated organoids lacked enterocytes, were larger and had more SOX9\textsuperscript{29} and Ki67\textsuperscript{29} cells, but displayed no change in Paneth cells (Fig. 2c). By contrast, atRA treatment resulted in an increase in the number of enterocytes (Extended Data Fig. 5e–g), but again no deficiency in Paneth cells. Interestingly, RXRI treatment at day 3 also did not result in nuclear translocation of YAP1 (Fig. 2c), suggesting that RXR is not involved in direct activation of YAP1, but rather controls its nuclear export, when the latter is already active. We then investigated vitamin A metabolism\textsuperscript{27,28} (Fig. 2d) and found that genes involved in retinoic acid metabolism were specifically expressed in enterocytes\textsuperscript{29,30}, in particular the gene encoding the retinaldehyde dehydrogenase ALDH1A1 (refs. 29,31,32; Extended Data Fig. 6a–d).

In organoids, a higher ALDH1A1 abundance and upregulation of retinoic acid response element (RARE) motifs were exclusive to enterocytes; however, in vivo a subset of crypt cells also displayed endogenous retinoic acid activity (Extended Data Fig. 5h–k). Aldha1a1-knockout organoids and organoids cultured from single cells under ALDH1A1 inhibition or vitamin A depletion had fewer enterocytes and more cycling cells—characteristics that could be reversed by treatment with atRA (Fig. 2e, f and Extended Data Fig. 5k–n). Interestingly, organoids cultured in medium lacking vitamin A did not display perturbed YAPI localization or symmetry breaking (Extended Data Fig. 5o). This suggests that retinoic acid metabolism is necessary for differentiation of enterocytes but not of Paneth cells (nor does it affect YAPI-expressing regenerative cells), and that enterocytes obtain regional specificity through ALDH1A1-controlled intracellular synthesis of atRA.

RXRI imposes a regenerative state

Retinoic acid receptor (RAR)-dependent signalling is important for enterocyte differentiation\textsuperscript{33}, while RXR activation maintains the balance between regeneration and enterocyte differentiation (Fig. 2). We confirmed that predicted RXR/RAR target genes were induced at day 3 and were associated with enterocyte functions, and that organoids treated with RXRI at day 3 retained the day 3 transcriptional signature, whereas treatment with atRA upregulated enterocyte-specific genes (Fig. 3a, Extended Data Fig. 7a–h and Supplementary Table 2). Time-course RNA sequencing starting from single cells (Supplementary Fig. 1) showed that, whereas control organoids transition from an early regenerative state (at days 1–3) to a mature state (from day 4 onwards), RXRI-treated organoids retained the regenerative transcriptome and atRA-treated organoids matured more quickly. At the level of individual genes, in the RXRi condition, YAP targets and genes associated with a fetal-like regenerative state\textsuperscript{34} were strongly and progressively upregulated, whereas treatment with atRA caused a decrease in the regenerative signature and rapid enterocyte maturation (Fig. 3b, c and Extended Data Fig. 8a–d).

The regenerative signature and targets of YAP were significantly upregulated only in organoids treated from day 0 (Fig. 3d and Extended Data Fig. 8e), confirming the role of RXRI in maintaining the active state of YAP1, rather than in activating it. Interestingly, fetal and YAP target genes include Clu (expressed in regenerative cells), Anxa1 (an oesophageal gene) and Anxa10 (a gastric gene), suggesting that the cells have multiple regional identities (Fig. 3c). Consistent with this, enterocyte genes were downregulated in both cases, whereas marker genes of Paneth cells were downregulated only in early treatment (Fig. 3d and Extended Data Fig. 8e). Comparing RXRI treatment with helmint infection\textsuperscript{35}, we observed suppression of the intestinal signature in both. By contrast, in the atRA condition, tissue specificity was acquired earlier (Extended Data Fig. 8f–h). Intestinal specification depends on tissue-specific transcription factors, such as Cdx2 and Pdx1\textsuperscript{36}. Cdx2-regulated genes decreased in expression at early time points and were re-expressed after day 3, as were intestine-specific genes. Cdx1 and Cdx2 expression was progressively downregulated in RXRI-treated organoids, whereas in the atRA condition and in enterocytes Cdx2 expression was increased (Extended Data Fig. 8i–m).

Finally, single-cell analysis revealed that day 4 organoids treated with RXRI resembled day 1 organoids, featuring upregulation of YAP target genes and regenerative signature genes, such as Anxa5, Anxa10 and Sca-1 (Fig. 3e and Extended Data Fig. 9a), albeit at higher levels. Under RXRI
Organoid development to improve regeneration of the intestine. RXR signalling with RXR antagonists as a potentially useful therapy regenerative phenotype in vivo, suggesting transient inhibition of longer time frames of crypt regeneration. These results validated the OLFM4+ stem cells (Extended Data Fig. 10j–l), probably owing to the crypts, and improved crypt morphology. We did not, however, detect drove a progressive accumulation of proliferating cells at the bottom of increase in goblet cells. RXRi increased the abundance of goblet cells, enterocytes (Extended Data Fig. 10g–l) showed an irradiation-induced Fig. 10d–f). Analysis of proliferating, stem, Paneth and goblet cells and (Fig. 3f and Extended Data Fig. 10a–c). In irradiated mice, RXRi treat-

Discussion

Here we established an image-based screening platform with which to characterize the phenotypic landscape of organoid development from a single screen, generating what is, to our knowledge, the first map of functional genetic interactions that govern intestinal organoid development and self-organization.

We then described two phenotypes that emerge following RXRi treatment, depending on the organoid stage. In early organoids, inhibition of RXR maintains the regenerative state (with nuclear YAP1) and prevents symmetry breaking, possibly by controlling the nuclear export of YAP1. After symmetry breaking, RXR activity is restricted to canonical retinoic acid signalling in enterocytes and is linked to ALDH1A1-dependent production of atRA. Retinol metabolism is important for maintaining the balance of cell types between enterocytes and undifferentiated progenitors, in agreement with its role in restricting proliferation.

During organoid formation, cells undergo regenerative reprogrammation, and not only lose cell-type specificity but also transiently acquire a more ‘generic’ identity, with a tendency to misexpress genes from more anterior gastrointestinal tissues, similar to the anteriorization observed in ulcerative colitis. RXR inhibition results in organoids that retain the expression of fetal-like and YAP target genes, and are unable to acquire mature cell types and undergo intestinal specification. We thus propose that RXR-mediated signalling acts as a ‘homing device’ upon exit from the regenerative state, ensuring activation of intestine-specific networks of transcription factors, including Cdx2 and its downstream targets. Indeed, Cdx2 knockout in intestinal organoids induces a transformation to gastric cells. Later in organoid development, when organoids
recapitulate homeostasis, RXR is crucial for retinoic acid signalling and enterocyte differentiation. The differences between the early regeneration potential in vivo and later differentiation-related phenotypes probably arise from enterocyte differentiation. The differences between the early regeneration potential in vivo RXR could have broader effects, affecting other components of the system. RXR is crucial for retinoic acid signalling and membrane trafficking.

Online content

Fig. 3 | RXRi treatment prevents exit from regenerative state and improves regeneration in vivo. a. Temporal expression of genes containing RAR or RXR motifs, normalized to expression at day 0. Solid lines show mean values; opaque interval show standard deviation; n values refer to the number of genes per group. b. Pearson’s correlations between gene-expression levels in time-course and compound experiments. c. Differential gene expression in organoids relative to DMSO at indicated time points. GC, goblet cell. d. Fold change relative to DMSO (day 4) for specific gene categories and cell-type markers at days 0 and 3. Data points represent individual genes; horizontal lines show fourfold enrichment or depletion; n, number of genes. e. tSNE maps generated from single-cell RNA sequencing data, colour-coded by sample (left) and by mean normalized expression of gene groups (right). Data points show single cells; sampling of 5,000; n, number of genes; colour map ranges are shown in plots. f. Change in body weight (AUC, area under curve) in treatment cohorts; n = 6 mice per cohort. g. Quantification of villus length; n, number of villi; measured in n = 3 independent samples per condition. In the images, tissues are stained with haematoxylin and eosin. a, c, d, log₂-transformed fold change (log₂FC). b, d, n = 4 independent cultures from 2 independent mice. d, f, g, boxes show quartile range while whiskers show value intervals; solid lines show median values. Two-sided t-test; asterisks indicate statistical significance; individual P values shown in plots.

1. Garabedian, E. M., Roberts, L. J., McNevin, M. S. & Gordon, J. I. Examining the role of Paneth cells in the small intestine by lineage ablation in transgenic mice. J. Biol. Chem. 272, 23729–23740 (1997).
2. Sato, T. et al. Paneth cells constitute the niche for Lgr5 stem cells in intestinal crypts. Nature 469, 415–418 (2011).
3. Marshman, E., Booth, C. & Potten, C. S. The intestinal epithelial stem cell. BioEssays 24, 91–98 (2002).
4. Bullen, T. F. et al. Characterization of epithelial cell shedding from human small intestine. Lab. Invest. 86, 1052–1063 (2006).
5. de Souza e Melo, F. & de Sauvage, F. J. Cellular plasticity in intestinal homeostasis and disease. Cell Stem Cell 24, 54–64 (2019).
6. Tetteh, P. W. et al. Replacement of lost Lgr5-positive stem cells through plasticity of their enterocyte-lineage daughters. Cell Stem Cell 18, 203–213 (2016).
7. van Es, J. H. et al. DII-secretory progenitor cells revert to stem cells upon crypt damage. Nat. Cell Biol. 14, 1099–1104 (2012).
8. Tian, H. et al. Opposing activities of Notch and Wnt signaling regulate intestinal stem cells and gut homeostasis. Cell Rep. 11, 53–63 (2015).
9. Joostens, S. P. J. et al. MET signaling mediates intestinal crypt-villus development, regeneration, and adenoma formation and is promoted by stem cell CD44 isoforms. Gastroenterology 153, 1040–1053 (2017).
10. Sato, T. et al. Single Lgr5 stem cells build crypt-villus structures in vitro without a mesenchymal niche. Nature 459, 262–265 (2009).
11. Chacón-Martínez, C. A., Koester, J. & Wickström, S. A. Signaling in the stem cell niche: regulating cell fate, function and plasticity. Development 145, dev155999 (2018).
12. Hung, J. et al. Proteomic changes during intestinal cell maturation in vivo. J. Proteomics 71, 530–546 (2008).
13. Caniters, L. J. et al. A novel approach to high-quality postmortem tissue procurement: the GTEx project. Biopreserv. Biobank. 13, 301–319 (2015).
14. Peeters, T. & Vantapren, G. The Paneth cell: a source of intestinal lysosome. Gut 16, 553–558 (1979).
15. VanDussen, K. L. et al. Notch signaling modulates proliferation and differentiation of intestinal crypt base columnar stem cells. Development 139, 488–497 (2012).
16. Yin, X. et al. Niche-independent high-purity cultures of Lgr5+ intestinal stem cells and their progeny. Nat. Methods 11, 106–112 (2014).
17. Levine, J. H. et al. Data-driven phenotypic dissection of AML reveals progenitor-like cells that correlate with prognosis. Cell 162, 184–197 (2015).
18. Liberati, P., Snijder, B. & Pelkmans, L. A hierarchical map of regulatory genetic interactions in membrane trafficking. Cell 157, 1473–1487 (2014).
21. Snijder, B., Liberali, P., Frechin, M., Stoeger, T. & Pelkmans, L. Predicting functional gene interactions with the hierarchical interaction score. Nat. Methods 10, 1089–1092 (2013).
22. Andreu, P. et al. A genetic study of the role of the Wnt/beta-catenin signalling in Paneth cell differentiation. Dev. Biol. 324, 288–296 (2008).
23. Pinto, D., Gregorieff, A., Begthel, H. & Clevers, H. Canonical Wnt signals are essential for homeostasis of the intestinal epithelium. Genes Dev. 17, 1709–1713 (2003).
24. Sakaki, J. et al. Synthesis and structure-activity relationship of novel RXR antagonists: orally active anti-diabetic and anti-obesity agents. Bioorg. Med. Chem. Lett. 17, 288–296 (2007).
25. Pinto, D., Gregorieff, A., Begthel, H. & Clevers, H. Canonical Wnt signals are essential for homeostasis of the intestinal epithelium. Genes Dev. 17, 1709–1713 (2003).
26. Gregorieff, A., Liu, Y., Inanlou, M. R., Khomchuk, Y. & Wrana, J. L. Yap-dependent reprogramming of Lgr5+ stem cells drives intestinal regeneration and cancer. Nature 526, 715–718 (2015).
27. Borel, P. et al. Processing of vitamin A and E in the human gastrointestinal tract. Am. J. Physiol. Gastrointest. Liver Physiol. 280, G95–G103 (2001).
28. Lampen, A., Meyer, S., Arnhold, T. & Nau, H. Metabolism of vitamin A and its active metabolite all-trans-retinoic acid in small intestinal enterocytes. J. Pharmacol. Exp. Ther. 295, 979–985 (2000).
29. Haber, A. L. et al. A single-cell survey of the small intestinal epithelium. Nature 551, 333–339 (2017).
30. Goverse, G. et al. Diet-derived short chain fatty acids stimulate intestinal epithelial cells to induce mucosal tolerogenic dendritic cells. J. Immunol. 198, 2172–2181 (2017).
31. Molotkov, A. & Duester, G. Genetic evidence that retinaldehyde dehydrogenase Raldh1 (Aldh1a1) functions downstream of alcohol dehydrogenase Adh1 in metabolism of retinol to retinoid acid. J. Biol. Chem. 278, 36085–36090 (2003).
32. Bowles, J. et al. ALDH1A1 provides a source of meiosis-inducing retinoic acid in mouse fetal ovaries. Nat. Commun. 7, 10845 (2016).
33. Ordóñez-Morán, P., Dafflon, C., Inagaki, M., Nishida, E. & Huelskens, J. HOXAS counteracts stem cell traits by inhibiting Wnt signaling in colorectal cancer. Cancer Cell 28, 875–829 (2015).
34. Nusse, Y. M. et al. Parasitic helminths induce fetal-like reversion in the intestinal stem cell niche. Nature 559, 109–113 (2018).
35. Gao, N., White, P. & Kaestner, K. H. Establishment of intestinal identity and epithelial-mesenchymal signaling by Cdk2. Dev. Cell 16, 588–599 (2009).
36. Spence, J. R. et al. Directed differentiation of human pluripotent stem cells into intestinal tissue in vitro. Nature 470, 105–109 (2011).
37. Kim, T. H. & Shioda, R. A. Genetic evidence that intestinal Notch functions vary regionally and operate through a common mechanism of Math1 repression. J. Biol. Chem. 296, 11427–11433 (2011).
38. Bhattacharya, N. et al. Normalizing microbiota-induced retinoic acid deficiency stimulates protective CD8+ T-cel-mediated immunity in colorectal cancer. Immunity 43, 641–655 (2016).
39. Dotti, I. et al. Alterations in the epithelial stem cell compartment could contribute to permanent changes in the mucosa of patients with ulcerative colitis. Gut 66, 2069–2079 (2017).
40. Serafini, E. P., Kirk, A. P. & Chambers, T. J. Rate and patter of epithelial cell proliferation in ulcerative colitis. Gut 22, 648–652 (1981).
41. Simmini, S. et al. Transformation of intestinal stem cells into gastric stem cells on loss of transcription factor Cdk2. Nat. Commun. 5, 5728 (2014).
42. Evans, R. M. & Mangelsdorf, D. J. Nuclear receptors, RXR, and the big bang. Cell 157, 255–266 (2014).
43. Cassani, B., Villablanca, E. J., De Calisto, J., Wang, S. & Mora, J. R. Vitamin A and immune regulation: role of retinoic acid in gut-associated dendritic cell education, immune protection and tolerance. Mol. Aspects Med. 33, 63–76 (2012).
44. Rangan, P. et al. Fasting-mimicking diet modulates microbiota and promotes intestinal regeneration to reduce inflammatory bowel disease pathology. Cell Rep. 26, 2704–2719 (2019).
Methods

Animal experiments and intestinal organoid lines
Experiments involving the irradiation-induced injury model were approved by the Internal Animal Care and Use Committee (IACUC) and conducted according to IACUC guidelines at the Genomics Institute of the Novartis Research Foundation. For the irradiation study, eight-week-old male C57BL/6J mice (Jackson Labs) were used in groups of six, as this is the smallest sample size needed to achieve a significant difference, based on prior model validation. Only males were used, as they are predicted to be more resilient in this model than females, with a steadier loss of body weight and less reproductive tissue covering the intestine; use of females could affect the penetrance of the γ-irradiation dose, introducing more variability. All mice were randomized or assigned groups on a cage-by-cage basis, based on the animals’ body weight on the first day of study. It was not possible to randomize on a per-mouse basis (that is, individually) as males will fight if not housed with brothers. The animals were eight weeks old (approximately 25 g) at the start of the experiments, as this size and weight provide the best fit to the dimensions of the shielding device used for irradiation to induce injury. No blinding was performed; the researchers knew which mice were in which group during data analysis. All other animal experiments were approved by the Basel Cantonal Veterinary Authorities and conducted in accordance with the Guide for Care and Use of Laboratory Animals. Male and female outbred mice between 7 and 15 weeks old were used for all other experiments. Mouse lines used were wild-type C57BL/6 (Charles River Laboratories and Jackson Labs), Fucci2 (a gift from J. Skotheim, Stanford University, CA) and Cdx2–EGFP (a gift from K. McDole, MRC LMB, Cambridge, UK).

Organoid culture
Organoids were generated from isolated crypts of mouse small intestine as described.
Organoids were kept in IntestiCult organoid growth medium (Stem Cell Technologies) with 100 μg ml⁻¹ penicillin–streptomycin for amplification and maintenance. For a detailed description, see Supplementary Methods.

Image-based screening assays
For a detailed description, see Supplementary Methods. In brief, organoids were collected 5–7 days after passaging and digested with TriplLE (Invitrogen) for 20 min at 37 °C. Isolated cells were collected in ENR medium, composed of advanced DMEM/F-12 with 15 mM HEPES (Stem Cell Technologies) supplemented with 100 μg ml⁻¹ penicillin–streptomycin for amplification and maintenance. For an acetyl analogue by palladium coupling. The compound was tested for its ability to inhibit the transactivation of human RXR-α in order to determine its half maximal inhibitory concentration (IC₅₀) values, as follows: inhibition of 9-cis-retinoic acid-induced RXR-α transactivation, 3 μM (BioAssay AID 292628); inhibition of LG-100268-induced RXR-α transactivation, 3.3 μM (BioAssay AID 292627).

Treatment of intestinal organoids with compounds
In the indicated experiments, we used the following compounds: ABLHAI inhibitors A37 (Tocris, catalogue number S802) and NCT-501 (Tocris, catalogue number 5934); RXRA agonists NRX 194204 (Axon Med Chem, catalogue number 2408) and all-trans retinoic acid (Sigma, catalogue number R2625); RXR-α/RAR-α (RXRA/RARA) agonist 9-cis-retinoic acid (Sigma, catalogue number R4643); RXR antagonists Cdp2170 (ref. 24; a gift from Novartis) and HX 531 (Tocris, catalogue number 3912).

RXR antagonist
The RXR antagonist (Cdp2170) identified in the screen and used for follow-up studies (Figs. 2, 3 and Supplementary Table 2) was a gift from Novartis. The molecule is a diazepinylbenzoic acid derivative (International Union of Pure and Applied Chemistry (IUPAC) name 4-(2-acetyl-5-ethyl-7,7,10,10-tetramethyl-8,9-dihydropyranophosphor-2,3-b-(1,5) benzodiazepin-12-y)-3-fluorobenzoic acid; ChEMBL ID CHEMBL395962). It was synthesized using hydroxy-diazeppinylbenzoc acid as a precursor for an acetyl analogue by palladium coupling.

Experiments in fixed organoid samples
Organoids were collected 5–7 days after passaging and digested with TriplLE (Invitrogen) for 20 min at 37 °C. Dissociated cells were passed through a cell strainer with a pore size of 20 μm. For indicated experiments, single living cells were sorted by fluorescence-activated cell sorting (FACS; Becton Dickinson FACSAria cell sorter). Forward scatter and side scatter properties were used to remove cell doublets and dead cells. Single cells were derived from wild-type C57BL/6 organoids unless indicated otherwise. Resuspended cells were mixed with Matrigel (Corning) in a medium to Matrigel ratio of 1:1, plated in 96-well plates (Greiner, catalogue number 655090) in 3.5 μl droplets and exposed to the indicated compounds. All compound stocks were prepared in DMSO, and DMSO was used as a vehicle control. Organoids were treated and fixed at the indicated time points to generate samples for immunofluorescence imaging.

Organoid culture for RNA sequencing
Wild-type C57BL/6J organoids were collected 5 days after passaging and digested with TriplLE (Invitrogen) for 20 min at 37 °C. Experiments were performed in duplicate for two independent biological samples (organoid cultures produced from two C57BL/6 male littermate mice). Dissociated cells were passaged through a cell strainer with a pore size of 20 μm. Single living cells were sorted by FACS (Becton Dickinson FACSAria cell sorter). Forward scatter and side scatter properties were used to remove cell doublets and dead cells (Supplementary Fig. 1). Resuspended cells were mixed with Matrigel (Corning) in a medium to Matrigel ratio of 1:1 and plated in 24-well plates in 50 μl droplets. From day 0 to day 3, WENRC medium (described above in the section ‘Image-based screening assays’) was used for organoid culture. From days 3 to 5, ENR medium was used for organoid culture.

Our compound library (a gift from Novartis) was composed of 2,789 compounds (Supplementary Table 1) in the form of 1 mM solutions in DMSO. Every library plate contained 12 active controls (6 wells containing the γ-secretase inhibitor DAPT and 6 wells containing the GSK-3β inhibitor CHIR99021 (Stem Cell Technologies, catalogue number 72054)) and 12 vehicle controls (DMSO). Compound treatments were performed from day 0 by adding 10 μl of 25 μM intermediate dilutions of the compound library in WENRC medium to achieve a final concentration of 5 μM. Compound treatment was repeated at day 3 by using compound library dilutions in ENR, prepared as above.

Generation of organoid lines
To generate organoids expressing retinoic acid response elements (RAREs) tagged with green fluorescent protein (GFP), we infected...
wild-type C57BL/6 organoids with in-house-produced pGreenFire 1–RARE viral particles (System Biosciences, catalogue number TR037PA-1) or, as a control, with pEGIP (Addgene, plasmid number 26777) at 0 h. For a detailed explanation of single guide RNA (sgRNA) design in CRISPR–Cas9-mediated gene-knockout experiments and the production of lentiviral particles, see Supplementary Methods.

Organoid culture in medium without vitamin A
In the indicated experiments, organoids were cultured in medium with or without vitamin A. To prepare the medium, 1× B27 minus vitamin A (Thermo Scientific) was used instead of 1× B27 (Thermo Scientific) to prepare both ENR and WENRC media. To allow proper comparison, in these experiments, B27 minus vitamin A (Thermo Scientific) was supplemented with retinyl acetate (Merck, catalogue number 46958) corresponding to the standard B27 supplement in order to produce medium for control conditions.

Preparation and imaging of fixed samples
To allow imaging of all organoids within a similar z-range, we centrifuged the contents of each well plate at 3,000 rpm for 10 min in a pre-cooled centrifuge at 10 °C before fixation. Organoids were fixed at indicated time points in 4% paraformaldehyde (PFA; Electron Microscopy Sciences) in phosphate-buffered saline (PBS) for 45 min at room temperature.

For image-based screening assays, organoids were permeabilized with 0.5% Triton X-100 (Sigma-Aldrich) for 1 h and blocked with 3% fetal calf serum (FCS; Sigma-Aldrich) in PBS with 0.1% Triton X-100 for 1 h. Primary and secondary antibodies were diluted in blocking buffer and applied as described in Supplementary Table 3. For detailed procedures, see Supplementary Methods.

In all samples, high-throughput imaging was carried out using an automated spinning disk microscope from Yokogawa (CellVoyager 7000S). For imaging, an intelligent imaging approach was used ('search first' module of Wako Software Suite, Fujifilm Wako Automation Corporation). For detailed procedures, see Supplementary Methods.

Primary antibody labelling
Anti-lysozyme antibody (EC3.2.1.17, Dako) was labelled with CF568 fluorophore using a labelling kit, Mix-N-Stain (Biotium), according to the manufacturer's instructions.

Image analysis and extraction of features
Organoid segmentation in maximum intensity projections (MIPs). For each acquired confocal z-stack field, MIPs and sum intensity projections (SIPs) were generated from all acquired z-planes per field. All MIP fields belonging to the same well were stitched together to obtain MIP well overviews for each channel. The high-resolution well overviews were used for organoid segmentation and feature extraction. Each individual organoid was automatically segmented on the basis of either its CellTrace signal (image-based screening assay) or its DAPI signal (all other imaging assays). To allow precise segmentation, clumped objects were separated using edge information (Canny edge detection algorithm) and subsequent watershedding with imposed minima.

Features in MIPs. For each segmented organoid, a total of 34 features, describing shape and intensities for each acquired channel, were extracted. A further 60 features describing Zernike polynomials were extracted and used for object filtering as described below. MIPs were used to describe fluorescence distribution and the morphological features of organoids. A subset of features was selected for multivariate feature analysis on the basis of information content and covariance as described below.

Features in SIPs. SIPs were used to extract features relating to total intensity per object to allow accurate quantification. In the image-based screen, SIP projections were used to extract all features for the segmented objects.

Feature selection for image analysis
Extracted features were analysed for covariance to exclude highly correlated (and anticorrelated) features; for details, see Supplementary Methods. In all imaging experiments, extracted features were normalized using z-score normalization within respective assay plates.

Detection of segmentation artefacts by SVMs
A linear support vector machine (SVM) was trained on a dataset of 100 randomly picked individual organoids with correct segmentation and 100 organoids with observed segmentation artefacts. Features used for SVM prediction consisted of the 9 features used for PhenoGraph analysis, and also included 60 Zernike polynomials.

Filtering of sparse conditions
For image-based screening assays, conditions with fewer than ten organoids detected per well were discarded from the analysis. In other assays, the threshold level for sparse conditions was assessed on an assay-to-assay basis; in general, all conditions with less than 20% of the mean organoid count in the given assay were discarded.

Generation of phenotypic signatures
Phenotypic clustering was carried out using the entire dataset (402,930 organoids) with the feature set defined in Extended Data Fig. 1, using the software package PhenoGraph (MATLAB implementation; https://github.com/dpeelab/cyt3) as above. The abundance of every phenotypic class was calculated as the fraction of organoids belonging to the class in every individual condition. Abundance was z-score-transformed within assay plates to minimize plate effects. For detailed procedures, see Supplementary Methods.

Hit selection
Individual treatment conditions were ranked by reproducibility between replicates. The reproducibility score was defined as the correlation coefficient for 15-element phenotypic fingerprints of respective conditions. Conditions with a reproducibility score of more than 0.5 and a z-score value for phenotypic class abundance of more than 1.5 or less than −1.5 for any of the classes were included in the hit list. Conditions with a z-score value for phenotypic class abundance of more than 4 or below −4 for any of the classes were selected for validation.

Hit validation with randomization trials
To calculate statistical parameters, we carried out a randomization trial, reshuffling the phenotypic class labels randomly between the 400,000 organoids in the dataset. Cluster cardinalities were kept, as the pool of class labels has not been altered. The z-scored abundances of phenotypic classes in every condition were then calculated from 1,000 trials to estimate the probability that a given condition would reproducibly (with correlation between replicates used as the cutoff parameter) present a significant phenotypic change after level permutation. For detailed procedures, see Supplementary Methods.

Target-gene-enrichment score
To ensure that the hit list was not prone to contain genes targeted by a high number of compounds in the initial library, we calculated a target-gene-enrichment score (S enr) as described in Supplementary Methods.

HIS calculations
Hierarchical interaction scores were calculated as described21 using the 15-element phenotypic fingerprints as inputs. The resulting interaction matrix was used to infer edges for generation of a network of phenotypic interactions. For further analysis, only those genes that were connected by edges with HIS values of more than 0.2 were kept.
Subnetworks were identified using the Cytoscape implementation of the ClusterOne algorithm\(^4\). For visualization purposes, only edges with the highest HIS value per node were kept.

**STRING validation of HIS predictive power**
We used a prediction model, calculating the predicted number of edges for a set of genes that are retained when a sliding HIS threshold is applied (Extended Data Fig. 4b). For the detailed procedure, see Supplementary Methods.

**Co-annotation analysis**
A progressive HIS threshold with steps of 0.005 was applied to the list of inferred HIS interactions, to eliminate those genes that are not connected by HIS interactions at a given threshold. The optimal value for the HIS threshold was calculated by using the percentage of gene pairs connected by retained HIS interactions that are co-annotated with Kyoto Encyclopedia of Genes and Genomes (KEGG) or Gene Ontology (GO) terms. The resulting first infliction point (defined as the absence of a gene-pair dropout between two subsequent steps of the sliding threshold) was used as the HIS threshold for generating the functional interaction network (Fig. 1b).

**Annotation enrichment analysis**
Annotation enrichment analysis was performed using the ClueGo plugin for Cytoscape\(^4\). The enrichment of KEGG functional annotations (\textit{Homo sapiens} and \textit{Mus musculus} KEGG pathways, version of 1 March 2017) was calculated against the corresponding background (all detected genes for RNA-sequencing (RNA-seq) experiments, and a list of the unique targets of the compound library (Supplementary Table 1) for the image-based screen).

**Annotation enrichment analysis in HIS network**
For annotation enrichment analysis in the network of HIS interactions (Fig. 1), the minimal number of genes was adjusted according to subnetwork size in the range two to four genes.

**Annotation enrichment analysis in RNA-seq data**
For annotation enrichment analysis using the RNA-seq dataset (Fig. 3), a minimal number of three genes was used, and only those annotations with an enrichment \(P\)-value (two-tailed hypergeometric test with Bonferroni correction) of less than 0.05 were included.

**RNA purification for bulk RNA sequencing**
RNA was isolated using a single-cell RNA purification kit (Norgen Biotek Corporation, catalogue number 51800), pooling 3 wells of organoid culture from 24-well plates (wild-type C57BL/6 background). Organoids were seeded as single cells at 50,000 cells per well and cultured as described above. Organoids were treated with compounds at either day 0 or day 3 in the relevant experiments. RNA purification was performed in duplicate for two organoid cultures (wild-type C57BL/6, male littermate mice) from the samples included in the single-cell RNA-seq experiment. Cell-type identities of single cells were defined on the basis of mean expression levels of cell-type marker genes\(^3\).

**Analysis of single-cell RNA-seq**
TSNE maps were generated from normalized read counts for dimensionality reduction and used to display the expression levels of gene categories in single cells from the samples included in the single-cell RNA-seq experiment. Cell-type identities of single cells were defined on the basis of mean expression levels of cell-type marker genes\(^3\).

**Analysis of transcription-factor-binding motifs**
Analysis of transcription-factor-binding sites was performed using HOMER (version 4.8; http://homer.ucsd.edu/homer/motif/) as described\(^3\). For detailed procedures, see Supplementary Methods.

**Correlation with published datasets**
For cross-correlation studies with published RNA-seq datasets, raw data were obtained from the Gene Expression Omnibus (GEO; https://www.ncbi.nlm.nih.gov/geo/) repository: helminth infection in mouse intestine\(^3\), GEO accession number GSE97405; tissue of organoid development\(^3\), GEO accession number GSE11595; Cdc2 knockout organoids\(^3\), GEO accession number GSE62784. Data were processed from read counts as above.

To identify tissue-specific genes, we selected all genes from the GTEx repository (https://gtexportal.org/), mapping the human genes to their respective mouse orthologues. Analysis was performed as in the Supplementary Information.

**Irradiation-induced injury and RXRi dosing**
Eight-week-old male C57BL/6J mice (Jackson Labs) were weighed and divided into groups on day 0. Mice were exposed to 20 Gy \(\gamma\)-irradiation. For detailed procedures, see Supplementary Methods.

**Tissue collection and histology**
Mice were euthanized using an overdose of isoflurane and cervical dislocation on either day 2 (3 h post final dose of RXR antagonist, 3 total doses), day 4 (16 h post final dose, 6 total doses), day 5 (40 h post final dose, 6 total doses) or day 6 (65 h post final dose, 6 total doses). Small intestines were collected and cleaned using cold Hank’s balanced salt solution (HBSS; Hyclone) and fixed in a Swiss roll conformation with 10% neutral buffered formalin in PBS (Avantik) for 48 h at room temperature before transfer into 70% ethanol. Small-intestine Swiss rolls were embedded in paraffin (Sakura Tissue Tek) and 5-μm longitudinal serial sections were cut using a Leica RM2255. For detailed procedures, see Supplementary Methods.

**Immunohistochemical imaging of tissue samples**
The 5-μm longitudinal serial sections of small-intestine Swiss rolls embedded in paraffin (described above) were mounted on glass slides and used for deparaffinizing with UltraClear reagent. Deparaffinized samples were used for sodium-citrate-based antigen retrieval. Stained slides were mounted with precision coverslips using ibidi mounting medium (ibidi) and used for imaging with a high-throughput confocal microscope as above to generate MPLs from confocal z-stacks. For detailed procedures, see Supplementary Methods.

**Quantification of villus length**
Individual villi were measured in ImageJ in jejunal regions of the histologically stained longitudinal serial sections of small-intestine Swiss rolls. For every condition, at least three regions from at least two mice were used per time point and per treatment.
Statistics and reproducibility
The investigators were not blinded to allocation during experiments and data analysis. The allocation of wells for experimental conditions was randomly assigned. All statistics were calculated on the basis of independent replicates, unless stated otherwise in figure legends. Statistical significance was determined by two-sided t-test, unless stated otherwise in figure legends. No statistical methods were used to predetermine sample size. Experiments were repeated at least twice, except the following experiments, which were carried out once: the image-based screen was performed once in two independent replicates from two independent mice; bulk and RNA-seq time courses were performed in n = 4 individual replicates from n = 2 independent mice; the in vivo irradiation time course was performed in cohorts of n = 6 independent mice per treatment condition. In vivo irradiation study, performed with a single terminal time point (day 6), was repeated twice with similar results.

Reporting summary
Further information on research design is available in the Nature Research Reporting Summary linked to this paper.

Data availability
All RNA-seq data generated here (bulk RNA-seq data (compound treatment at day 3), bulk RNA-seq data (compound treatment at day 0) and single-cell RNA-seq data) are available at the GEO under accession number GSE147136. The RXR antagonist used here (Cpd2170) is available through a material transfer agreement (MTA) with Novartis. The source data for following figures are available in the manuscript files: Figs. 1a, b, 2a, f, 3a–d, f, g and Extended data Figs. 1c–i, 2a–h, 3a–f, 4b–d, i, j, 5b, j–l, 6b, c, 7b, d–g, i, 8a–l, 9a, b, f, g, 10b, e, f, h. Gene sets used for visualization in Fig. 3e and Extended Data Fig. 9c–e, g are provided in Supplementary Table 2. Source data are provided with this paper.

Code availability
Code used for image analysis was developed in the Liberali laboratory using MATLAB and Python 3. Segmentation for the image-based screen was performed using code developed in the Liberali laboratory in MATLAB, and is available at https://github.com/fmi-basel/glib-lukonin-et-al-2020. The code for organoid two-dimensional segmentation and feature extraction in other assays is available at https://github.com/fmi-basel/glib-nature2018-materials.

Acknowledgements
We thank D. Vischi, S. Iftikhar and E. Tagliavini for IT support; L. Gelman for assistance and training; H. Kohler for sorting; S. Smallwood for sequencing; and L. Pelkmans, J. Betschinger, C. Tsiairis, S. Gasser and laboratory members for reading the manuscript. This work received funding from the European Research Council (ERC) under the European Union’s Horizon 2020 research and innovation programme (grant agreement number 758617) and from the Swiss National Foundation (POOP3_157531 to P.L.).

Author contributions
P.L. conceived and supervised the study. P.L. and I.L. designed the experiments. J.J. designed the annotated compound library. I.L. and K.V. performed the image-based screen. I.L. performed the image analysis. L.C.M. designed CRISPR–Cas9 guides and carried out cloning. F.M. and I.L. performed lentivirus production and organoid preparations. I.L. performed imaging and transcriptomics experiments. M.B.S. designed the analysis of transcription-factor motifs. I.L., D.S. and M.B.S. analysed RNA-seq data. J.B., R.Z., K.C. and S.M. designed, performed and analysed the mouse irradiation study. P.L. and I.L. wrote the paper.

Competing interests
P.L. and I.L. are inventors on the patent application EP19182782.3, filed on 27 June 2019, with the title ‘Promoting tissue regeneration’, pertaining to the use of RXR antagonists as therapeutic agents in tissue regeneration. The patent applicant is the Friedrich Miescher Institute for Biomedical Research. Other authors declare no competing interests.

Additional information
Supplementary information is available for this paper at https://doi.org/10.1038/s41586-020-2776-9.

Correspondence and requests for materials should be addressed to P.L.

Reprints and permissions information is available at http://www.nature.com/reprints.
Extended Data Fig. 1 | See next page for caption.
Extended Data Fig. 1 | Reproducibility of the image-based screen. **a,** An example image (MIP of a confocal z-stack) of an organoid, with annotated regions along the major axis, and showing antibody staining for lysozyme (Lyz) and aldolase B (Aldob). Lysozyme-positive Paneth cells are indicated by white arrowheads. Scale bar, 50 μm. **b,** Left, an example image of a stitched well-level overview. Scale bar, 100 μm. Middle, enlarged regions from the left panel. Scale bar, 100 μm. Right, segmentation masks, with object unique identifier numbers overlaid. **a, b,** Representative images of the DMSO control condition, repeated in n = 471 independent replicates with similar results. **c,** Top, reproducibility of detected organoid counts in replicas of the library plates. Heat map of Pearson’s correlation of organoid counts in screen replicates, with plate replicates grouped by parent library plates as indicated; n = 384 wells per plate. Bottom, heat map of standard deviation of organoid size (z-scored organoid area) for respective well positions. Passive and active controls are in wells outlined by the white box. n = 18 independent plates. **d,** Left, covariance matrix of the 34 extracted features, clustered by covariance (c-means clustering, ten clusters). Ch, channel; StdIntensity, standard deviation of intensity. Right, heat map showing principal component loading of the extracted features; bar chart above, eigenvalues of first ten principal components. **e,** Top, changes in the accuracy of the naive Bayes predictor throughout the backwards-feature-elimination test. Bottom, final set of nine features (‘Algorithm-selected’) and list of features used as input for clustering with PhenoGraph. **f,** Distribution of mean values per well of the indicated features in active and passive control conditions. CHIR is the GSK3β inhibitor CHIR99021; DAPT is a γ-secretase inhibitor. Centre line, median; boxes, quartile range; individual data points overlaid. Two-sided t-test, with P-values shown in the plot. MeanInt, mean intensity. n = 471, 100 and 101 independent samples for the DMSO, CHIR99021 and DAPT conditions respectively. **g,** Z-scored organoid features used for clustering, shown for individual well positions of in-plate replicates of active and passive control conditions. n = 6, 6 and 20 wells per plate for DAPT, CHIR and DMSO respectively; shown are mean values over n = 18 assay plates. D, DAPI; Eccentr., eccentricity, Integr. Int., integrated intensity; Mass disp., mass displacement for the indicated immunofluorescence channels; Std Int., standard deviation of intensity. **h,** Mean z-scored values for the indicated features per well from the entire dataset, sorted in ascending order. Every data point is an average value per well, with conditions colour-coded as in the key. n = 5,250 independent samples measured in the screen. **i,** tSNE maps colour coded for z-scored values of indicated features (left to right: eccentricity, organoid area, mean intensity of aldolase B and mean intensity of lysozyme antibody staining) and PhenoGraph classification. Every data point represents an individual organoid, with sampling stratified by PhenoGraph assignment. The sample size is 5,000 individual organoids.
Extended Data Fig. 2 | See next page for caption.
Extended Data Fig. 2 | Robust phenotypic signatures. a, Top, phenotypic clusters and phenotypic groups (see Fig. 1b) identified using the multivariate feature array, and heat map of mean z-scored values per class for the indicated feature array. Aldob, aldolase B; Ar, area; D, DAPI; Ecc, eccentricity; II, integrated intensity; Lyz, lysozyme; MD, mass displacement; MI, mean intensity; SI, standard deviation of intensity; Sh, shape. n = 40,624, 34,265, 20,134, 31,687, 2,549, 702, 23,643, 48,992, 30,791, 21,342, 23,610, 32,773, 19,172, 41,931 and 29,939 organoids for classes 1–15 respectively. Bottom, phenotypic class assignment for organoids in control conditions; outer circle colour, phenotypic group; inner circle colour, assigned phenotypic cluster; n = 7367, 7982 and 33,395 individual organoids for DAPT, CHIR99021 (CHIR) and DMSO conditions respectively. b, Potential loss of phenotypic resolution owing to phenotype grouping. Three phenotypic clusters are assigned to the ‘regenerative’ phenotype, but the exact 15-element phenotypic signature differs depending on whether PORCN or GSK3β is inhibited. Mean of n = 100, 4, 2 and 2 independent replicates for CHIR99021, Cpd2170, Cpd420 and Cpd1772 respectively. c, Top, relative z-score transformed abundances of 15 phenotypic clusters, shown as means ± s.d. Bottom, heat maps showing individual and mean phenotypic signatures for 50 replicates of the indicated control conditions. n = 50 sampled independent replicates for all 3 conditions. d, Left, randomization trial for reshuffling of phenotypic class labels in the entire dataset. Right, scatter plots and histograms showing the distribution of replica correlation and maximum class variance in permuted and non-permuted data for the selected and filtered conditions. Red dashed lines show the original selection stringency. e, Distribution of calculated P-values in the indicated groups of conditions. Top, scatter plot and kernel density estimation; bottom, box plots. Boxes, quartile range; whiskers, value interval with excluded outliers; solid lines, median values. n = 2,242 unique conditions corresponding to 5,204 individual wells. n = 279, 15 and 1,948 conditions for ‘hit’, ‘hit (one replica)’ and ‘not selected’ groups respectively. f, Top left, mean z-scored values per identified phenotypic class for the indicated feature array. Bottom left, heat map representation of the phenotypic signature for the indicated compounds, grouped by the most abundant phenotype in the original screen. Top right, tSNE map colour coded for the highest enriched phenotypic clusters. Every data point represents a compound. tSNEs were calculated from phenotypic signatures. Bottom, calculated reproducibility values per compound and numbers of replicates used for analysis of the indicated compounds. The replica count is the number of non-sparse (n > 10 organoids) independent wells recorded per condition. Assay performed in n = 8 independent replica from 2 independent organoid cultures. g, Flowchart depicting filtering of the screened conditions. h, tSNE maps colour coded for the highest enriched phenotypic clusters as indicated; every data point represents either a compound condition (top; n = 301 compound conditions) or a unique target gene-modality pair (bottom; n = 207 target genes); tSNEs calculated from 15-dimensional phenotypic signatures.
Extended Data Fig. 3 | See next page for caption.
Extended Data Fig. 3 | Identification of hit compounds and target genes.

**a**, Top, compound abundance in the library and hit list. Bottom, distribution of enrichment scores for targets of the screen hits. Every data point represents a unique target-gene–modality pair.  

**b**, Heat map showing phenotypic signatures for genes with a compound coverage of at least three compounds per gene. Heat map rows marked by arrowheads show compounds used as representative conditions per target.  

**c**, Left, contingency table for two-sided Fischer’s exact test; right, bar plot and box plot of P-value distributions in the indicated compound condition groups. High conf. hits, high-confidence hits. In the box plot, boxes show quartile ranges; whiskers show value intervals with excluded outliers; centre lines show median values. n = 699, 167 and 29 unique target genes for non-hits, other hits and high-confidence hits respectively.  

**d**, Enrichment and false discovery rate for functional annotation enrichments reported by the STRING database tool (https://string-db.org/) for the list of 29 target genes.  

**e**, Top left, Venn diagram showing the distribution of target genes by compound coverage. Main panel, network of functional interactions for the set of genes with high-compound coverage and hitlist specific enrichment. Edges show interactions known in the STRING database; thickness and line type represent the STRING combined score (see network key); nodes show unique target genes; node outlines show phenotypic clusters with the highest enrichment; circles indicate groups of similar functional annotations.  

**f**, Enrichment of KEGG terms (percentage of genes annotated with KEGG terms) in conditions from the hit list where the highest enriched phenotype is either ‘regenerative’ or ‘enterocyst’. Values are sorted by corresponding P-values (two-sided test based on hypergeometric distribution with Bonferroni correction). n = 59 and 61 genes for the enterocyst and regenerative phenotypes, respectively.
Extended Data Fig. 4 | See next page for caption.
Extended Data Fig. 4 | Validation of HIS predictive power and screen hits.

a, Principle of the hierarchical interaction score (HIS). HIS is calculated pairwise for a set of genes described by multivariate phenotypic signatures (left), to generate a matrix of graded interactions (middle) in which every interaction contains information on which readout contributed the most. In the resulting HIS-based network (right), the strength of the interactions (the thickness of the edges) reflects the similarity of the observed enrichment or depletion, and directionality is from the gene with the broader set of effects to the gene with the narrower set of effects.

b, Heat maps of the HIS pairs for \( n = 207 \) target genes; interactions with non-zero HIS values are shown colour-coded for the phenotypic class that contributes the most to HIS inference (left) or for the HIS value (right).

c, Top left, number of retained nodes; bottom left, number of STRING-reported and predicted edges (see Supplementary Methods); centre, fold enrichment of reported STRING interactions over prediction; right, percentage of co-annotated gene pairs with increasing HIS threshold cutoff (top right, KEGG co-annotations; bottom right, GO co-annotations (levels 5–15)). Red dashed line, HIS threshold (0.175); arrowheads, inflection points.

d, Percentage of co-annotated gene pairs in indicated sets of genes in measured and randomized data (top, KEGG co-annotations; bottom, GO co-annotations (levels 5–15)). The corresponding number of genes is drawn either from the genome or the hitlist pool, as indicated.

e, HIS-based interaction network for β-catenin. Node colour shows the highest enriched phenotypic class; edge colours show the phenotypic class contributing the most to HIS value inferences (see key); edge arrow shapes show HIS-inferred directionality. All edges directed to/from β-catenin are shown.

f, Inducible NICD–GFP and HES1–GFP knock-in organoids with and without doxycycline (dox) treatment from day 0, showing loss of Paneth cells in NICD-overexpressing organoids. Nuclei are stained with DAPI (blue); lysozyme is stained with antibody (red).

Scale bar, 50 μm.

g, Day 5 puromycin-selected lentiCRISPRv2-mediated Casr knockout (CasrKO) organoids, with corresponding infection and selection controls (pLenti–EF1–EGFP organoids). Organoids were cultured from single cells in the indicated conditions. The upper six images show the perturbed crypt phenotype and lack of phenotypic response to CaCl\(_2\) treatment in CasrKO organoids. Bottom, lentivirally introduced EGFP expression after puromycin selection. Scale bars, 30 μm.

h, Top two rows, day 3 and day 5 puromycin-selected control (pLenti–EF1–EGFP) organoids; bottom row, lentiviral Akt1-overexpressing (Akt1 OE) organoids cultured from single cells, showing perturbed phenotypes and lack of enterocyte differentiation. Scale bars, 30 μm.

i, Top, organoids from DMSO control and RXR antagonist conditions analysed in the screen. Scale bar, 50 μm. Bottom, corresponding phenotypic signatures. \( n = 2, 2 \) and \( 1 \) non-sparse (\( n > 10 \) organoids) independent replica for Cpd2170, Cpd2390 and Cpd2173, respectively.

j, Abundance of phenotypic cluster 13 in hit conditions with a reproducibility of more than 0.5. Compounds targeting RXR and RAR are depicted with coloured dots. Histograms show distributions of respective values. \( n = 301 \) independent conditions. Microscopy images shown in f–i are MIPs of confocal z-stacks.

f–h, Assays performed in \( n = 12 \) independent replica from 2 independent organoid cultures with similar results.
Extended Data Fig. 5 See next page for caption.
Extended Data Fig. 5 | Profiling the effects of treatment with an RXR antagonist.

a, Images of organoids cultured in the presence of an RXR agonist (RXRa) in the indicated treatment conditions. Scale bar, 50 μm. Assay performed in \( n = 12 \) (DMSO) or \( n = 6 \) (other conditions) independent replica from 2 independent organoid cultures.

b, Top, distribution of mean aldolase B staining intensity in control organoids and those treated at day 4. Bottom, abundance of the ‘enterocyst’ phenotype in the indicated conditions. Error bars show standard deviations between \( n = 6 \) (DMSO) or \( n = 3 \) (other conditions) independent replica. Assays were performed with the same number of replicas from two independent organoid cultures with similar results.

c, Images of organoids fixed at indicated time points, showing antibody staining for lysozyme. Scale bar, 20 μm.

d, Top two rows, images of organoids from Fucci2 mice, expressing a dual-colour cell-cycle reporter (mVenus–hGem(1/110), G2/M-phase reporter; mCherry–hCdt1(30/120), G1-phase reporter) cultured with or without RXR antagonist (RXRi), fixed at day 4. Top row, expression of mVenus–hGem(1/110) (FUCCI (G2/M)), mCherry–hCdt1(30/120)(FUCCI (G1)); bottom row, antibody staining for YAP1. Scale bar, 100 μm. Bottom row, enlargements of those areas outlined in the middle row. Scale bar, 20 μm.

e, Images of organoids following 10 μM atRA treatment at day 3. Top row, scale bar, 50 μm. Bottom row, scale bar, 10 μm.

f, Organoids fixed at day 5, 48 h after switch to ENR medium. Scale bar, 100 μm.

g, Top, distribution of mean SOX9, and bottom, ki67 staining intensity in control and ALDH1A1-knockout organoids. Organoids were fixed at day 5, 48 h after switching to ENR medium. Violin ranges extended by one standard deviation. Two-sided \( t \)-test; \( P \)-values shown in the plot.

h, Images of wild-type organoids cultured in the indicated conditions from single cells.

i, Images of organoids expressing RARE–dsGFP at day 4. dsGFP, destabilized GFP; scale bar, 10 μm. Assay performed in \( n = 12 \) independent replicas from \( n = 3 \) independent organoid cultures with similar results.

j, Histological images of mouse small intestinal epithelium from RARE–LacZ mouse. Regions along the crypt–villus axis are indicated. A single crypt flanked by villus regions, outlined in the left panel, is shown in blue at the right. Scale bar, 50 μm. Experiment performed in \( n = 4 \) independent histological samples from \( n = 2 \) independent mice with similar results.

k, Left, RARE–dsGFP organoids in the indicated treatment conditions. Scale bar, 60 μm. Right, DAPI-normalized sum intensity (norm. int.) of RARE–dsGFP reporter and aldolase B in individual organoids. Data points represent individual organoids, color-coded according to treatment as indicated. \( R^2 \), Pearson’s correlation coefficient. 1, Left, puromycin-selected ALDH1A2-knockout organoids. Scale bar, 50 μm. Right, ALDH1A1 staining intensity in control and ALDH1A1-knockout organoids. \( n = 36 \) and 17 organoids for control and ALDH1A1-knockout conditions respectively. *** \( P < 5 \times 10^{-18} \), two-tailed \( t \)-test.

l, Left, puromycin-selected ALDH1A2-knockout organoids. Scale bar, 50 μm. Right, ALDH1A1 staining intensity in control and ALDH1A1-knockout organoids. \( n = 36 \) and 17 organoids for control and ALDH1A1-knockout conditions respectively. *** \( P < 5 \times 10^{-18} \), two-tailed \( t \)-test.

m, Images of organoids treated as indicated from day 0. ALDH1A1i, 5 μM ALDH1A1 inhibitor; atRA, 10 μM all-trans retinoic acid. Scale bar, 50 μm. Assay performed in \( n = 8 \) independent replica.

n, Images of organoids treated with RXR antagonist from day 0 in medium with or without vitamin A. Organoids were fixed at day 5, 48 h after switch to ENR medium. Scale bar, 50 μm.

o, Wild-type organoids cultured in medium with or without vitamin A. Scale bar, 100 μm.

p, Organoids cultured in medium with or without vitamin A and fixed at the indicated time points. Scale bar, 20 μm.
Extended Data Fig. 6 | See next page for caption.
Extended Data Fig. 6 | Retinol metabolism in enterocytes. a, Network representation of annotation enrichment analysis for a published RNA-seq dataset describing marker genes of intestinal epithelium cell types. Small nodes represent genes; large nodes represent functional annotations; edge thickness show gene-annotation assignments (grey) or term-term relations (black). Colours indicates cell-type specificities of annotations (see key). b, Box plots showing expression (in log₂-normalized transcripts per kilobase million (TPM) values) of Aldh1a1, Aldh1a2 and Aldh1a3 across cell types in the published single-cell RNA-seq (scRNA-seq) dataset. Boxes show quartile ranges; whiskers represent value intervals with excluded outliers; middle lines show median values. Each data point represents a single cell. EC, enterocyte; TA, transient-amplifying. n = 1,522 single cells. c, Expression (in log₂-normalized transcript counts) of Aldh1a1, Aldh1a2 and Aldh1a3 across indicated treatment conditions in scRNA-seq (Fig. 3 and Extended Data Fig. 9). Sampling of n = 3,000 single cells. d, tSNE maps of the scRNA-seq experiment. Each data point represents a single cell, colour-coded by expression (log₂-normalized transcript counts) of indicated genes in samples of the scRNA-seq experiment (Fig. 3). Ranges of the colour mapping are indicated in each plot. Sampling of n = 5,000 single cells. Each data point represents a single cell. arRA, 10 μM all-trans retinoic acid; DMSO, DMSO control; RXRi, 5 μM RXR antagonist; w/o VitA, vitamin-A-depleted medium.
Extended Data Fig. 7 | See next page for caption.
Extended Data Fig. 7 | Transcriptional signature of organoids treated with RXR antagonist. **a**, Motif enrichments in the 1,000-base-pair regions that are centred on promoters of genes that are more highly expressed at a given day compared with the average from the whole period of organoid development. **b**, Enrichment heat map of transcription-factor-binding motifs at the transition from day 3 to day 4. Genes are binned by expression pattern. **c**, Network of functional annotation (KEGG) terms specifically enriched in genes containing RXR- and RAR-containing transcription-factor-binding motifs. Nodes show annotation terms; edges represent term–term interactions; node colours show annotation groups (see key). **d**, Principal component (PC) analysis of RNA-seq samples from the indicated treatment conditions and time points. The scatter plot shows the first two principal components. \( n = 4 \) (2 independent organoid cultures each from 2 independent mice) for all individual conditions. **e**, Pearson’s correlation values between samples of the time-course RNA-seq experiment and compound-stimulation RNA-seq experiment. \( n = 12,025 \) genes detected in both datasets. **f**, Left, expression of selected genes in untreated organoids at day 3 and in the indicated treatment conditions 24 h after treatment. Every data point represents a gene, colour-coded according to assigned cluster label (\( k \)-means clustering). Stratified sampling of 1,884 genes; \( n = 50 \) genes per cluster. FDR, false discovery rate. Top right, mean expression of genes from respective clusters in the RXR-antagonist condition compared with the DMSO control (log, fold change, log, FC). Data shown as means ± s.d. \( n = 152, 102, 196, 361, 396, 109, 113, 290 \) and 165 for expression-profile clusters 1–9 respectively. **g**, tSNE maps colour-coded according to assigned cluster labels (\( k \)-means clustering). Left, tSNEs calculated from expression values measured in the bulk RNA-seq experiment (e). Right, genes showing treatment-specific upregulation and downregulation in the orthogonal compound condition. Every data point represents a gene. **h**, Annotation enrichment analysis (GO terms) for gene categories described in **g**. Asterisks depict statistical significance determined with two-tailed hypergeometric test with Bonferroni correction. *\( P < 0.05 \); **\( P < 2 \times 10^{-3} \); ***\( P < 2 \times 10^{-6} \). **i**, Left, expression of genes reported to have biased expression in the indicated gastrointestinal-tract tissues during unperturbed intestinal organoid development. log2-transformed count per million (CPM) values are normalized to mean expression over all samples. Solid lines show mean expression per time point; opaque intervals show standard deviation. \( n = 83, 20, 63, 156, 259, 45 \) and 31 genes for colon (sigmoid), colon (transverse), oesophagus (junction), oesophagus (mucosa), not specific, small intestine and stomach respectively. Middle, expression of genes specific to the indicated gastrointestinal tissues in RXRi-treated organoids and DMSO controls after 24 h of treatment. Right, expression of small-intestine-specific genes in DMSO- and RXRi-treated organoids. Boxes show quartile ranges; whiskers denote value intervals with excluded outliers; middle lines show median values. ***\( P < 2 \times 10^{-19} \) (two-tailed t-test). **d–i**, atRA, 10 μM all-trans retinoic acid; 9cisRA, 10 μM 9-cis-retinoic acid; DMSO, DMSO control; RXRi, 5 μM RXR antagonist. **g, i**, log2-transformed CPM values, normalized to mean expression over all samples.
Extended Data Fig. 8 | See next page for caption.
Extended Data Fig. 8 | Organoids treated with an RXR antagonist lose intestinal identity. **a**, Principal component analysis of RNA-seq samples (treated at day 0) from different treatment conditions and time points. The scatter plot shows the first two principal components. **b**, Pearson’s correlation values between samples of the time-course RNA-seq experiment. **n** = 13,502 genes detected in all samples. **c**, Normalized gene expression (in log; CPM) of the indicated genes in samples of the time-course RNA-seq experiment (Fig. 3b). **d**, Expression of genes from the indicated categories in treatment conditions at days 1 and 5 of organoid development. Data points represent genes. **n** = 14 and 16 genes for intestinal cell type markers and fetal-like and YAP target genes respectively (gene names are in **b**). **e**, Normalized gene expression in contrast (RXRi-treated over DMSO control, at day 4) for samples treated at days 0 and 3. Left and middle, colours show cell-type markers (left) or indicated gene categories (middle); dashed lines are at fourfold enrichment or depletion; opaque areas cover genes not significantly perturbed in either contrast; data points represent genes; colours represent indicated gene categories; marker types highlight the genes of interest. Right, only those genes that were upregulated on transition from day 0 to day 1 in the DMSO control are shown. Red dashed lines are at fourfold enrichment. Marker types highlight the genes of interest. **f**, Expression of genes grouped by response to intestinal helminth infection 34. Expression is quantified by log; CPM, normalized to the mean expression over all samples in the respective datasets. Solid lines show mean values per time points; opaque intervals show standard deviations; dashed lines show fourfold enrichment or depletion. **g**, Normalized expression (log; CPM) of genes differentially regulated in helminth infection 34 at day 4 (top) and day 5 (bottom). Each data point represents a gene; **n** = 141 and 286 genes for infection-upregulated and -downregulated genes respectively. **h**, Expression of tissue-specific genes over time points and treatments (DMSO, atRA and RXRi). log; CPM, normalized to mean expression over all samples; dashed lines show fourfold enrichment or depletion. **n** = 63, 156, 259, 45 and 31 genes for oesophagus (junction), oesophagus (mucosa), not specific, small intestine and stomach respectively. **i**, Top, expression of tissue-specific genes (**n** = 156, 259, 45 and 31 genes for oesophagus (mucosa), not specific, small intestine and stomach respectively), and bottom, expression of genes regulated by Cdx2 (**n** = 340, 170 and 11,378 genes for Cdx2-upregulated, Cdx2-downregulated and not affected respectively) in unperturbed organoid development. log; CPM, normalized to mean expression over all samples. **j**, Left, fold changes for the indicated genes in the indicated contrasts over the time-course RNA-seq experiment (Fig. 3b). Right, normalized gene expression in the indicated contrasts for samples treated at days 0 and 3: dashed lines show fourfold enrichment or depletion; the opaque area covers genes not significantly perturbed in either contrasts; colours show the indicated gene categories; every data point represents a gene. **n** = 340, 170 and 11,378 genes for Cdx2-upregulated, Cdx2-downregulated and not affected respectively. **k**, Expression of genes regulated by Cdx2 in organoids over the time course of the experiment. Solid lines show mean values per time point; opaque intervals show standard deviations; dashed lines show fourfold enrichment or depletion. **l**, Left panels, wild-type organoids at day 3 cultured from single cells; images are composite MIPs; scale bar, 10 μm. Right, intensity of Cdx2 staining; boxes show quartile ranges; whiskers show value intervals with excluded outliers; solid lines show median values. Asterisks indicate statistical significance; two-sided *t* -test; *P* -values are as follows: DMSO versus RXRi, 2.04 × 10^{-22}; DMSO versus atRA, 8.17 × 10^{-7}; atRA versus RXRi, 5.84 × 10^{-19}; **n**, number of organoids analysed in each condition. **m**, Cdx2–EGFP organoids at day 4, cultured from single cells. Images are composite MIPs. Scale bars, 50 μm. The right two columns show YAP1 and Cdx2 staining from respective composite images. Assay performed in **n** = 16 independent replicates from **n** = 2 independent organoid cultures with similar results. **f**, **h**, **i**, **k**, **l**, **m**, Solid lines show mean values per time points; opaque intervals show standard deviations. atRA, 10 μM all-trans retinoic acid; DMSO, DMSO control; RXRi, 5 μM RXR antagonist.
Extended Data Fig. 9 | See next page for caption.
Extended Data Fig. 9 | scRNA-seq analysis of phenotypes produced by RXRi treatment. a, Left, tSNE maps from scRNA-seq. Each data point represents a single cell, colour-coded by sample (see key). \( n = 4,787, 3,570, 5,365, 4,963, 5,576 \) and 5,304 single cells for day 4 DMSO, RXRi, atRA and vitamin A-free, and day 1 DMSO control samples 1 and 2 respectively. Right, expression (log\(_2\) normalized transcript counts) of indicated genes in samples of the scRNA-seq experiment (Fig. 3); sampling of \( n = 3,000 \) cells. b, Cell-type composition of scRNA-seq samples. Confidence cutoffs for cell-type assignment were set individually for each cell type on the basis of the mean expression levels of marker genes from ref. 29; \( n = 29,565 \) single cells. c–e, tSNE maps of our scRNA-seq experiment, colour coded by mean normalized expression (log\(_2\)-transformed counts) of gene groups. c, Expression of cell-type signature genes from ref. 29. The numbers of genes per cell-type signature are shown in individual plots. d, Expression of genes that are differentially regulated following intestinal helminth infection\(^{34}\). e, Expression of genes with biased expression in tissues (GTEX database; https://gtexportal.org/home/). f, Left, partial tSNE maps (top) and density map (bottom) of single cells from the RXR-antagonist-treated sample of the scRNA-seq experiment. In the density map, the \( x \) and \( y \)-axes show the mean expression (mean of log\(_2\)-transformed counts) of genes from the indicated categories. Colours show cell counts in respective bins. Red dashed lines show cutoffs used to assign populations. Right, tSNE maps of the scRNA-seq experiment, showing assigned identities in the RXR-antagonist-treated sample. g, Left, average expression of genes in populations of cells as assigned in f. Colours depict the log\(_2\)-transformed fold change (log\(_2\)FC) in the ‘early progenitor’ population compared with the ‘regenerative identity’ population. Every data point represents a gene. Centre, log\(_2\)FC values of the indicated genes. Green, absorptive-lineage-specific genes; blue, secretory-lineage-specific genes. Right, tSNE maps of the scRNA-seq experiment colour-coded by mean normalized expression (log\(_2\)-transformed counts) of genes with log\(_2\)FC values of greater than 0.5 between ‘early progenitors’ and ‘regenerative’ populations. a, b, atRA, 10 \( \mu \)M all-trans retinoic acid; DMSO, DMSO control; RXRi, 5 \( \mu \)M RXR antagonist; w/o VitA, vitamin-A-depleted medium. a–f, In tSNE maps each data point represents a single cell; sampling of 5,000 single cells. c–e, g, Ranges of colour mapping and numbers of genes per category (\( n \)) are indicated in each plot.
Extended Data Fig. 10 | See next page for caption.
Extended Data Fig. 10 | Treatment with an RXR antagonist improves intestinal regeneration in an irradiation-induced mouse model of colitis.

**a**, Irradiation-induced colitis model. PK, pharmacokinetic analysis. **b**, Change in body weight in the indicated treatment cohorts over the time frame of the study. Data shown are mean ± s.d values for cohorts of *n* = 6 independent mice per cohort. Non-irr., non-irradiated vehicle-treated cohort. **c**, Images of spleen extracted from mice from the indicated treatment cohorts. Scale bar, 1 cm.

**d**, Small-intestine ‘Swiss rolls’ from mice belonging to the indicated treatment cohorts and time points. Scale bar, 5 mm. **e**, Top, haemoccult score of stool samples from the indicated treatment cohorts; middle lines show mean; error bars show ± s.d.; *n* = 6 independent animals per cohort. Bottom, representative images of the haemoccult samples corresponding to the quantitative haemoccult scores. **f**, Serum levels of the RXRi compound at 7 h post-treatment at the indicated time points in RXRi-treated mice. Middle lines show means; error bars show ± s.d.; *n* = 6 independent animals per cohort. **g**, Top, small-intestine Swiss roll, showing the ileum, duodenum and jejunum. Scale bar, 5 mm. Middle, jejunum part of the intestine. Scale bar, 250 μm. Bottom, enlarged view of villi units; individual are villi indicated with arrowheads; the shaded area indicates measured villi length. Scale bar, 250 μm. **h**, Top, abundance of goblet cells, measured by staining with alcian blue, in histological samples at day 6 in mice from the indicated groups. Bottom, quantified percentage of alcian blue (AC)-positive cells in the entire intestine of mice from the indicated treatment cohorts. Boxes show, quartile ranges; whiskers show value intervals; solid lines show median values; individual data points are overlaid. *n* = 6 independent animals per cohort. **i**, Histological profiling of the abundance of Ki67+ cells in the intestinal epithelium at days 2, 4 and 6 in the indicated treatment cohorts. **j**–**l**, Histological profiling of the intestinal epithelium at days 2 (**j**), 4 (**k**) and 6 (**l**) extracted from mice from the indicated treatment cohorts. Left panels, haematoxylin and antibody staining for OLFM4; scale bars, 50 μm. Enlarged regions: upper insets, scale bars, 25 μm; lower insets, scale bars, 12 μm. Middle panels, nuclear fast red (NFR) and alcian blue staining; scale bars, 50 μm. Right panels, confocal imaging of histological sections (composite MIPs of z-stacks); scale bars, 50 μm. Enlarged regions: upper insets, scale bars, 25 μm; lower insets, scale bars, 12 μm. In all panels, experiments were carried out in *n* = 6 independent mice per treatment cohort with similar results. **c**, **d**, Representative images from respective treatment cohort animals. **g**–**l**, Representative images from *n* = 24 histological samples from *n* = 6 independent mice per treatment cohort. **b**–**h**, Day 6 (terminal time point) mouse study repeated twice with *n* = 6 mice per cohort with similar results.
Corresponding author(s): Prisca Liberali  
Last updated by author(s): Jun 26, 2020

Reporting Summary

Nature Research wishes to improve the reproducibility of the work that we publish. This form provides structure for consistency and transparency in reporting. For further information on Nature Research policies, see Authors & Referees and the Editorial Policy Checklist.

Statistics

For all statistical analyses, confirm that the following items are present in the figure legend, table legend, main text, or Methods section.

☐ The exact sample size (n) for each experimental group/condition, given as a discrete number and unit of measurement
☐ A statement on whether measurements were taken from distinct samples or whether the same sample was measured repeatedly
☐ The statistical test(s) used AND whether they are one- or two-sided
☐ Only common tests should be described solely by name; describe more complex techniques in the Methods section.
☐ A description of all covariates tested
☐ A description of any assumptions or corrections, such as tests of normality and adjustment for multiple comparisons
☐ A full description of the statistical parameters including central tendency (e.g. means) or other basic estimates (e.g. regression coefficient) AND variation (e.g. standard deviation) or associated estimates of uncertainty (e.g. confidence intervals)
☐ For null hypothesis testing, the test statistic (e.g. F, t, r) with confidence intervals, effect sizes, degrees of freedom and P value noted
☐ Give P values as exact values whenever suitable.
☐ For Bayesian analysis, information on the choice of priors and Markov chain Monte Carlo settings
☐ For hierarchical and complex designs, identification of the appropriate level for tests and full reporting of outcomes
☐ Estimates of effect sizes (e.g. Cohen’s d, Pearson’s r), indicating how they were calculated

Our web collection on statistics for biologists contains articles on many of the points above.

Software and code

Policy information about availability of computer code

Data collection
To collect imaging data, custom written segmentation code was used. The code was written in the Liberali lab and implemented with MATLAB 2016b (MathWorks). To collect imaging data, Wako Software Suite version 1 was used.

Data analysis
Code used for image analysis in this study was developed in the Liberali lab in Matlab and Python 3. Segmentation for the image-based screen was performed using code developed in Liberali laboratory in Matlab and is available under https://github.com/fmi-basel/glib-lukkonin-et-al-2020. The code for organoid 2D segmentation and feature extraction in other assays is available under https://github.com/fmi-basel/glib-nature2018-materials. To further analyze imaging data, Fiji (version 1.0) as well as MATLAB 2016b (MathWorks) were used. To analyze RNA-seq data, custom written R code (exact packages and parameters are described in the methods), DAVID Bioinformatics Resources 6.8 and JASPAR2018 Bioconductor package was used. Annotation enrichment analysis was performed using ClueGo plugin for Cytoscape (v. 3). Network analysis was performed using Cytoscape (v. 3) and Cytoscape plugins indicated in Methods. Subnetworks were identified using the Cytoscape implementation of the ClusterOne algorithm (Nepusz et al., 2012). Transcription Factor Binding Site Analysis was done using HOMER (version 4.8, http://homer.ucsd.edu/homer/motif/). Phenotypic clustering was done utilizing the software package PhenoGraph (Matlab implementation, https://github.com/dpeerlab/cyt3). For CRISPR-Cas9 mediated knockout, 20 bp long guide sequences were designed using online design tools (SYNTHEGO (https://www.synthego.com/products/bioinformatics/crispr-design-tool) or Broad institute GFP sgRNA Designer (https://portals.broadinstitute.org/gpp/public/analysis-tools/sgrna-design)). Genes expression level were quantified with the QuasR Bioconductor package (Chevrier et al., 2017), using gene annotations from the TxDb.Mmuscus.ucsc.mm10.knownGene Bioconductor package. Differentially expressed genes were determined with the package edgeR (version 3.20.5 (McCarthy et al., 2012)). The CellRanger suite (1.3.0) was used to generate the aggregated gene expression matrix in the single cell experiment.

For manuscripts utilizing custom algorithms or software that are central to the research but not yet described in published literature, software must be made available to editors/reviewers. We strongly encourage code deposition in a community repository (e.g. GitHub). See the Nature Research guidelines for submitting code & software for further information.
Data

Policy information about availability of data

All manuscripts must include a data availability statement. This statement should provide the following information, where applicable:

- Accession codes, unique identifiers, or web links for publicly available datasets
- A list of figures that have associated raw data
- A description of any restrictions on data availability

All RNA sequencing data generated in this study (bulk RNAseq data (compound treatment at day 3), bulk RNAseq data (compound treatment at day 0) and scRNA-seq) is available under the GEO accession number GSE147136 in the Gene Expression Omnibus repository. Source data behind following figures and panels are available in the manuscript files: Fig. 1a,b, 2a,f, 3a-d,f,g and Extended data Fig 1c-i, 2a-h, 3a-f, 4b-d,i,j, 5b,j,k,l, 6b,c, 7b,d-g,i, 8 a-l, 9a,b,f,g, 10b,e,f,h. Single-cell RNA sequencing data is available under the GEO accession number GSE147136, gene sets used for visualization in Fig. 3e and Extended Data Fig. 9c-e, g are given in the Supplementary Table 2. List of compounds used with chemical identifiers and information on commercial trade names and mode of action and target genes available in Supplementary Data Table 1. RXR antagonist used in this study (Cpd2170) is available through a Material Transfer Agreement (MTA) with Novartis. Processed RNA sequencing data are in Supplementary Data Table 2.

Field-specific reporting

Please select the one below that is the best fit for your research. If you are not sure, read the appropriate sections before making your selection.

- [ ] Life sciences
- [ ] Behavioural & social sciences
- [ ] Ecological, evolutionary & environmental sciences

For a reference copy of the document with all sections, see nature.com/documents/nr-reporting-summary-flat.pdf

Life sciences study design

All studies must disclose on these points even when the disclosure is negative.

Sample size

No sample size calculations were performed. In most cases, we assumed a minimum of around 100 organoids would be sufficient to recognize differences between control and perturbations based upon historical experiments in other contexts. For the image-based screen the entire dataset of ca. 400,000 individual organoids was used for clustering and generation of phenotypic signatures. For plotting purposes, such as visualization of tSNE maps, data was sampled to enable visualization of individual data points, using stratified sampling for relevant categories. In scRNAseq experiments, sample size of 5000 cells (ca. 1/6 of the entire dataset) was used for plotting, for the image based screen a sample of 5000 individual organoids was used for plotting tSNE maps.

Data exclusions

Exclusion criteria for quantitative imaging and RNA seq experiments were pre-defined. In image-based assays parameters used to exclude data points were defined based on data distributions, whereby Z-scored features were used to determine outliers, discarding organoids with 2-scored feature values below -10 and above 10. In the image-based screen and the validation screen organoids with segmentation artifacts were additionally excluded using feature-based SVM filtering. All valid objects were used for clustering, conditions with less than 10 valid organoids detected per well were excluded from the downstream analysis as having high false-positive probability for assessing relative phenotypic cluster abundance.

In the RNA sequencing analysis genes with less than two samples with at least one read per million reads were removed. In the single cell RNA sequencing analysis high quality cells have been selected based on the maximum second derivative of the UMI count distribution, and genes with 0 counts or negligible variance (coefficient of variation, CV< 0.001) across all libraries were removed.

Replication

Experiments were repeated at least twice with exception of the following experiments which were repeated once: image-based screen was performed once in 2 independent replicates from 2 independent mice. Bulk and RNA sequencing time course performed in n=4 individual replicates from n=2 independent mice, in vivo irradiation time course study (performed in cohorts of n=6 independent mice per treatment condition). In vivo irradiation study with single terminal time point (day 6) was repeated twice with similar results.

Randomization

Samples were randomly assigned.

Blinding

The same investigators both designed and performed experiments and data analysis, therefore blinding was not possible.

Reporting for specific materials, systems and methods

We require information from authors about some types of materials, experimental systems and methods used in many studies. Here, indicate whether each material, system or method listed is relevant to your study. If you are not sure if a list item applies to your research, read the appropriate section before selecting a response.
### Antibodies

**Antibodies used**

- Anti-AldolaseB Abcam (ab75751), 1:400 dilution
- Anti-ALDH1A1 Abcam (ab52492), 1:200 dilution
- Anti-Yap1 CST (#14074), 1:100 dilution
- Anti-Yap1 AF 488 conjugate CST (#147295), 1:100 dilution
- Anti-Yap1 AF 647 conjugate CST (#38707), 1:100 dilution
- Anti-Cdx2 Abcam (ab76541), 1:400 dilution
- Anti-pAkt1 CST (#2965), 1:400 dilution
- Anti-Lysozyme (EC3.2.1.17) DAKO (A0099), 1:400 dilution
- Anti-Lysozyme CF568 conjugate Produced in-house from Anti-Lysozyme (EC3.2.1.17) DAKO (A0099), 1:400 dilution
- Anti-Dll1 R&D Systems (AF3970), 1:100 dilution
- Anti-Ki67 CST (#11988), 1:200 dilution
- Alexa Fluor 488 donkey anti rabbit IgG Abcam (ab5450), 1:500 dilution
- Alexa Fluor 568 donkey anti rabbit IgG CST (#2586), 1:500 dilution
- Alexa Fluor 488 donkey anti mouse IgG Abcam (ab111125), 1:500 dilution
- Alexa Fluor 568 donkey anti mouse IgG CST (#39141), 1:500 dilution
- Alexa Fluor 488 donkey anti sheep IgG Abcam (ab16667), 1:500 dilution
- Alexa Fluor 568 donkey anti sheep IgG Thermo Fisher Scientific (A-21206), 1:500 dilution
- Alexa Fluor 647 donkey anti sheep IgG Thermo Fisher Scientific (A10042), 1:500 dilution

*Incubation times and conditions are provided in the Supplementary Table 3.*

**Validation**

Validation statements available from manufacturers:
- AldolaseB ([https://www.abcam.com/aldolase-b-antibody-epr3138y-ab75751.html](https://www.abcam.com/aldolase-b-antibody-epr3138y-ab75751.html)), anti-Yap ([https://www.cellsignal.com/products/primary-antibodies/yap-d8h1x-xp-rabbit-mab/14074](https://www.cellsignal.com/products/primary-antibodies/yap-d8h1x-xp-rabbit-mab/14074)), anti-Lysozyme ([https://www.agilent.com/en/product/immunohistochemistry/antibodies-controls/primary-antibodies/lysozyme-ec-3-2-1-17-(concentrate)-76124](https://www.agilent.com/en/product/immunohistochemistry/antibodies-controls/primary-antibodies/lysozyme-ec-3-2-1-17-(concentrate)-76124)), anti-Dll1 ([https://www.rndsystems.com/products/mouse-rat-dll1-antibody_af3970](https://www.rndsystems.com/products/mouse-rat-dll1-antibody_af3970)), additional validated in ref: "Distinct expression patterns of Notch ligands, Dll1 and Dll4, in normal and in inflamed mice intestine,"
- anti-Ki67 ([https://www.abcam.com/ki67-antibody-sp6-ab16667.html](https://www.abcam.com/ki67-antibody-sp6-ab16667.html)), anti-ALDH1A1 ([http://www.abcam.com/aldh1a1-antibody-epi1933y-ab52492.html](http://www.abcam.com/aldh1a1-antibody-epi1933y-ab52492.html)), anti-Cdx2 ([https://www.abcam.com/cdx2-antibody-epr2764y-ab276641.html](https://www.abcam.com/cdx2-antibody-epr2764y-ab276641.html)),
- anti-pAkt1 ([https://www.cellsignal.com/products/primary-antibodies/phospho-akt-thr308-c31e5e-rabbit-mab/2965](https://www.cellsignal.com/products/primary-antibodies/phospho-akt-thr308-c31e5e-rabbit-mab/2965)), Alexa Fluor 488 donkey anti rabbit IgG ([https://www.thermofisher.com/antibody/product/Donkey-anti-Rabbit-IgG-H-L-Highly-Cross-Adsorbed-Secondary-Antibody-Polyclonal/A-21206](https://www.thermofisher.com/antibody/product/Donkey-anti-Rabbit-IgG-H-L-Highly-Cross-Adsorbed-Secondary-Antibody-Polyclonal/A-21206)), Alexa Fluor 568 donkey anti rabbit IgG ([https://www.thermofisher.com/antibody/product/Donkey-anti-Rabbit-IgG-H-L-Highly-Cross-Adsorbed-Secondary-Antibody-Polyclonal/A10042](https://www.thermofisher.com/antibody/product/Donkey-anti-Rabbit-IgG-H-L-Highly-Cross-Adsorbed-Secondary-Antibody-Polyclonal/A10042)), Alexa Fluor 488 donkey anti mouse IgG ([https://www.thermofisher.com/antibody/product/Donkey-anti-Mouse-IgG-H-L-Highly-Cross-Adsorbed-Secondary-Antibody-Polyclonal/A-21202](https://www.thermofisher.com/antibody/product/Donkey-anti-Mouse-IgG-H-L-Highly-Cross-Adsorbed-Secondary-Antibody-Polyclonal/A-21202)), Alexa Fluor 568 donkey anti mouse IgG ([https://www.thermofisher.com/antibody/product/Donkey-anti-Mouse-IgG-H-L-Highly-Cross-Adsorbed-Secondary-Antibody-Polyclonal/A10037](https://www.thermofisher.com/antibody/product/Donkey-anti-Mouse-IgG-H-L-Highly-Cross-Adsorbed-Secondary-Antibody-Polyclonal/A10037)), Alexa Fluor 488 donkey anti goat IgG ([https://www.thermofisher.com/antibody/product/Donkey-anti-Goat-IgG-H-L-Cross-Adsorbed-Secondary-Antibody-Polyclonal/A-11055](https://www.thermofisher.com/antibody/product/Donkey-anti-Goat-IgG-H-L-Cross-Adsorbed-Secondary-Antibody-Polyclonal/A-11055)), Alexa Fluor 568 donkey anti goat IgG ([https://www.thermofisher.com/antibody/product/Donkey-anti-Goat-IgG-H-L-Cross-Adsorbed-Secondary-Antibody-Polyclonal/A-11057](https://www.thermofisher.com/antibody/product/Donkey-anti-Goat-IgG-H-L-Cross-Adsorbed-Secondary-Antibody-Polyclonal/A-11057)), Alexa Fluor 488 donkey anti sheep IgG ([https://www.thermofisher.com/antibody/product/Donkey-anti-Sheep-IgG-H-L-Cross-Adsorbed-Secondary-Antibody-Polyclonal/A-11015](https://www.thermofisher.com/antibody/product/Donkey-anti-Sheep-IgG-H-L-Cross-Adsorbed-Secondary-Antibody-Polyclonal/A-11015)), Alexa Fluor 568 donkey anti sheep IgG ([https://www.thermofisher.com/antibody/product/Donkey-anti-Sheep-IgG-H-L-Cross-Adsorbed-Secondary-Antibody-Polyclonal/A21099](https://www.thermofisher.com/antibody/product/Donkey-anti-Sheep-IgG-H-L-Cross-Adsorbed-Secondary-Antibody-Polyclonal/A21099)), Alexa Fluor 647 donkey anti sheep IgG ([https://www.thermofisher.com/antibody/product/Donkey-anti-Sheep-IgG-H-L-Cross-Adsorbed-Secondary-Antibody-Polyclonal/A-21448](https://www.thermofisher.com/antibody/product/Donkey-anti-Sheep-IgG-H-L-Cross-Adsorbed-Secondary-Antibody-Polyclonal/A-21448)).

### Eukaryotic cell lines

**Policy information about** [cell lines](https://www.abcam.com/cell-lines).

**Cell line source(s)**

| Lenti-X 293T (Takara Bio Group) | were used for lentivirus production. | Fucci2 organoid line (kind gift of Jan Skotheim, Stanford) |

---

**Involved in the study**

- Antibodies
- Eukaryotic cell lines
- Palaeontology
- Animals and other organisms
- Human research participants
- Clinical data

**Methods**

- ChIP-seq
- Flow cytometry
- MRI-based neuroimaging
| Cell line source(s) | University, Stanford, United States) was produced from R26p-Fucci2, Tg(Gt(ROSA)26Sor-mCherry/CD71,-mVenus/GMNN) mice. Cdx2-EGFP (kind gift from Katie McDole, MRC LMB, Cambridge, United Kingdom) was produced from Cdx2tm1Yxz mice. All other cell lines were generated from mouse intestine of the mice described in the Methods section. |
| Authentication | None of the cell lines used were authenticated. |
| Mycoplasma contamination | All cell lines were regularly tested for mycoplasma and were found negative. |
| Commonly misidentified lines (See ICLAC register) | No commonly misidentified lines were used in this study. |

### Animals and other organisms

#### Policy information about studies involving animals

- ARRIVE guidelines recommended for reporting animal research

#### Animals

| Laboratory animals | For the irradiation study, 8-week old male C57BL/6J mice (Jackson labs) were used in groups of groups of n=6 as this is the lowest sample size needed to achieve significant difference based on prior model validation. Males were used exclusively (males are predicted to be more resilient in this model than females with steady BW loss and less reproductive tissue covering the intestine). Experiments using females could hence affect penetrance of gamma dose to induce injury, introducing more variability. All mice were randomized or assigned groups on a cage-basis based on BW on the first day of study. It was not possible to randomize on a per mouse basis/individually as animals used were males and will fight if not housed with cage-mate brothers. All mice were aged 8 weeks at start (approximately 25g) this size/weight was the best fit for the dimensions of the shielding device used for irradiation to induce injury in the efficacy model. No blinding was performed, in vivo personnel and pathologist knew which mice were in which group during analysis of data. All other animal experiments were approved by the Basel Cantonal Veterinary Authorities and conducted in accordance with the Guide for Care and Use of Laboratory Animals. Male and female outbred mice between 7 and 15 weeks old were used for all other experiments. Mouse lines used: C57BL/6 wild type (Charles River Laboratories and Jackson labs), Fucci2 (kind gift from Jan Skotheim, Stanford University, Stanford, United States), Cdx2-EGFP (kind gift from Katie McDole, MRC LMB, Cambridge, United Kingdom). |
| Wild animals | The study did not involve wild animals. |
| Field-collected samples | The study did not involve field-collected samples. |
| Ethics oversight | Experiments using the irradiation-induced injury model were approved by Internal Animal Care and Use Committee (IACUC) and conducted according to Internal Animal Care and Use Committee guidelines at the Genomics Institute of the Novartis Research Foundation. All other animal experiments were approved by the Basel Cantonal Veterinary Authorities and conducted in accordance with the Guide for Care and Use of Laboratory Animals. Note that full information on the approval of the study protocol must also be provided in the manuscript. |

### Flow Cytometry

#### Plots

- The axis labels state the marker and fluorochrome used (e.g. CD4-FITC).
- The axis scales are clearly visible. Include numbers along axes only for bottom left plot of group (a 'group' is an analysis of identical markers).
- All plots are contour plots with outliers or pseudocolor plots.
- A numerical value for number of cells or percentage (with statistics) is provided.

#### Methodology

| Sample preparation | Murine organoids were collected 5-7 days after passaging and digested with TriplE (Invitrogen) for 20 min at 37 °C. Dissociated cells were passed through a cell strainer with a pore size of 20 μm. |
| Instrument | BD FACS Aria III (Becton Dickinson) was used for sorting |
| Software | BD FACS Diva 8.0.1 was used for collection |
| Cell population abundance | FACS was used to sort single live cells |
| Gating strategy | To remove debris, dead cells and cell doublets SSC-A/FSC-A gating, SSC-H/SSC-W gating and FSC-H/FSC-W gating were used. |
- Tick this box to confirm that a figure exemplifying the gating strategy is provided in the Supplementary Information.